ACUT (Accustem Sciences) Debt-to-Equity: 0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACUT Accustem Sciences Inc ACUT
27 GF Score
Price $0.23
! 1 Warning Sign
View Full Analysis

What is Accustem Sciences Debt-to-Equity?

Accustem Sciences ACUT +12.20% 27 Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus rates ACUT with a GF Score™ of 27/100. The stock has 1 warning sign investors should review. Among 966 Biotechnology companies, Accustem Sciences ranks worse than 103519.57% on this metric.

Accustem Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.00 Mil. Accustem Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.00 Mil. Accustem Sciences's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $-3.87 Mil. Accustem Sciences's debt to equity for the quarter that ended in Mar. 2026 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Accustem Sciences's Debt-to-Equity or its related term are showing as below:

ACUT' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.76   Med: -0.03   Max: -0.01
Current: -0.01

During the past 4 years, the highest Debt-to-Equity Ratio of Accustem Sciences was -0.01. The lowest was -0.76. And the median was -0.03.

ACUT's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16 vs ACUT: -0.01

Accustem Sciences  (OTCPK:ACUT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Accustem Sciences Debt-to-Equity Related Terms

Accustem Sciences Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Accustem Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accustem Sciences Debt-to-Equity Chart

Accustem Sciences Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Debt-to-Equity
-0.76 -0.03 -0.01 -0.01

Accustem Sciences Quarterly Data
Mar21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.03 -0.02 -0.01 0.00

ACUT vs DCOY, BIXT, SPRC: Debt-to-Equity Comparison

For the Biotechnology subindustry, Accustem Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accustem Sciences Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Accustem Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Accustem Sciences's Debt-to-Equity falls into.


ACUT
27GF Score
Accustem Sciences Inc ACUT
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Accustem Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Accustem Sciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.023 + 0) / -3.402
=-0.01

Accustem Sciences's Debt to Equity Ratio for the quarter that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / -3.872
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Accustem Sciences (ACUT) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Accustem Sciences and its competitors. According to the industry distribution chart, Accustem Sciences ranks #999999 out of 966 companies in the Biotechnology industry.
Is Accustem Sciences' Debt-to-Equity too high?
Accustem Sciences' current Debt-to-Equity is 0.00. Based on the distribution chart, Accustem Sciences ranks #999999 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Accustem Sciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Accustem Sciences' Debt-to-Equity compare to DCOY and BIXT?
According to the Biotechnology industry distribution chart, Accustem Sciences ranks #999999 out of 966 companies for Debt-to-Equity. This places Accustem Sciences in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Accustem Sciences and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accustem Sciences's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accustem Sciences stock overvalued right now?
Accustem Sciences (ACUT) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Accustem Sciences' overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Accustem Sciences (ACUT), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Accustem Sciences Business Description

Address 420 Lexington Avenue, Suite 1402, New York, NY, USA, 10001
Accustem Sciences Inc is a clinical stage diagnostics company dedicated to improving quality of life and outcomes for the millions of people who are diagnosed with cancer each year. The company's product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services.
27GF Score

Get the complete analysis for ACUT

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.23
Price